The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
had a large impact on global health, travel, and economy. Therefore, preventative and …

INTRODUCTION A major goal of HIV-1 vaccine development is to identify immunogens capable
of inducing protective titers of broadly neutralizing antibodies (bNAbs) against circulating…

The envelope glycoprotein trimer mediates HIV-1 entry into cells. The trimer is flexible, fluctuating
between closed and more open conformations and sometimes sampling the fully open, …

Large-scale vaccination campaigns have prevented countless hospitalizations and deaths
due to COVID-19. However, the emergence of SARS-CoV-2 variants that escape from …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing
to disrupt personal lives, global healthcare systems, and economies. Hence, there is an …

Background Emerging and future SARS-CoV-2 variants may jeopardize the effectiveness of
vaccination campaigns. Therefore, it is important to know how the different vaccines perform …

Emerging SARS-CoV-2 variants of concern (VOCs) pose a threat to human immunity induced
by natural infection and vaccination. We assessed the recognition of three VOCs (B.1.1.7, B…

Background Presenting vaccine antigens in particulate form can improve their immunogenicity
by enhancing B cell activation. Findings We describe ferritin-based protein nanoparticles …

The development of native-like HIV-1 envelope (Env) trimer antigens has enabled the induction
of neutralizing antibody (NAb) responses against neutralization-resistant HIV-1 strains in …

Importance It has become common practice to offer immunocompromised patients with
hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are scarce. …